Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced...
Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a...
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has IP and know how in vaccine...
The cross-pollination of platforms enables the San Diego-based company to create a novel way of enhancing productivity to enable the next generation of biological therapeutics
SAN DIEGO, Sept. 18, 2023 /PRNewswire/ — Primrose Bio, Inc., a stand-alone private biotechnology company focused on developing state-of-the-art discovery and production systems for protein and nucleic acid medicines, has been established as a...
